Retatrutide vs Semaglutide — Research Comparison

Retatrutide and semaglutide are both long-acting incretin-class research peptides, but they sit at opposite ends of the receptor-target spectrum. Semaglutide is a single-receptor (GLP-1) agonist while retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors. This comparison summarises the published literature relevant to laboratory research.

At-a-glance comparison

| Attribute | Retatrutide | Semaglutide | |---|---|---| | Receptor target | GLP-1 + GIP + Glucagon (triple) | GLP-1 (mono) | | Class | Triple incretin agonist | GLP-1 receptor agonist | | Reported half-life | ~6 days | ~7 days | | Cited weight-loss in Phase 2 trials | ~24% at 48 weeks (12 mg) | ~15% at 68 weeks (2.4 mg) | | Energy expenditure | Increased (glucagon arm) | Neutral / mildly reduced | | First published year | 2023 | 2012 (research literature) | | Research format | Lyophilised vial | Lyophilised vial |

Mechanism — what each receptor adds

Semaglutide engages only the GLP-1 receptor, which in the published literature drives insulinotropic signalling, delayed gastric emptying, and central appetite suppression. Retatrutide adds two additional arms: GIP-receptor agonism (an additional insulinotropic and adipose-handling signal) and glucagon-receptor agonism, which is associated in published rodent and Phase 2 human-research data with increased hepatic energy expenditure and lipolysis.

Pharmacokinetics

Both compounds are long-acting C20-fatty-acid-conjugated peptides engineered for once-weekly subcutaneous dosing in published research protocols. Semaglutide's half-life is approximately 7 days; retatrutide's reported half-life is approximately 6 days. Both demonstrate dose-proportional exposure across the studied range.

Published research highlights

Semaglutide's research base is much larger by virtue of being older — STEP, SUSTAIN, PIONEER and SELECT programs span weight, glycaemia, and cardiovascular endpoints. Retatrutide's published research is concentrated in the TRIUMPH program; the most-cited Phase 2 result is approximately 24% mean body-weight reduction at 48 weeks at the 12 mg weekly dose, the largest mean reduction reported for any incretin-class agent at the time of publication.

Where they overlap, where they don't

Overlap: insulinotropic signalling, appetite suppression, gastric-emptying delay. Divergence: retatrutide's glucagon arm is associated in the literature with increased resting energy expenditure that semaglutide does not produce; semaglutide's mature cardiovascular-research dataset is not yet available for retatrutide.

Choosing one for a research protocol

For research into single-receptor GLP-1 biology, mature comparator data, or cardiovascular endpoints, semaglutide remains the most-referenced compound. For research into multi-receptor incretin combinations, energy-expenditure mechanisms, or maximum cited weight-loss magnitudes, retatrutide is the more current reference.

Frequently asked research questions

Is retatrutide more potent than semaglutide?

In the cited Phase 2 weight-loss endpoints, retatrutide produces a larger mean reduction at peak dose. Direct head-to-head trials between the two agents have not been published, so cross-trial comparisons should be interpreted with the usual caveats.

Why does retatrutide include glucagon-receptor agonism?

Glucagon-receptor agonism is associated in published research with increased hepatic glucose output and lipolysis — combined with strong GLP-1-driven appetite suppression, the net effect in the published trials is enhanced energy expenditure rather than hyperglycaemia.

How do reconstitution and storage differ?

Both are supplied as lyophilised powder for reconstitution in bacteriostatic water and stored refrigerated after reconstitution. See the Ares Research reconstitution and storage guides for details.

What's the next step up from retatrutide?

There is no published higher-order incretin agonist beyond triple at the time of writing. Survodutide (GLP-1 + glucagon dual) and tirzepatide (GLP-1 + GIP dual) sit between semaglutide and retatrutide on the receptor-target spectrum.

Related research

• Retatrutide research hub → /research/hubs/retatrutide
• Semaglutide research hub → /research/hubs/semaglutide
• Tirzepatide research hub → /research/hubs/tirzepatide
• Survodutide research hub → /research/hubs/survodutide

Research use only. All content on this page is provided for in-vitro and laboratory research purposes. No statements are intended for, and nothing on this page should be construed as, medical advice or a recommendation for human consumption.